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ABSTRACT 
Multiple myeloma (MM) is a haematological malignancy of plasma cells. It is caused by an 
uncontrolled proliferative behaviour of clonal B cells. Cancer Research UK reported around 
5820 new cases each year (2% of all cases) making it the 19th most common cancer. MM 
remains an incurable disease with a relapsing and a remitting course. The 5-year and 10-year 
survival rates in England are reported to be 52.3% and 29.1% respectively.  
However, clinical outcomes have improved significantly in the last decade because of the 
increased availability of novel agents (oral and parenteral) in UK clinical practice, prescribed 
using one of two main strategies: fixed duration therapy (FDT) or continuous therapy (CT). 
These agents demonstrated their safety and efficacy in large phase 3 randomised clinical 
trials. 
Real-world data remains equally as important as clinical trials because it allows the myeloma 
community to understand the global variations in clinical practice, and reported outcomes of 
these therapies in the real-world. Advanced age, frailty and co-morbidities often exclude real-
world patients from clinical trials. This created a gap in the literature about efficacy of novel 
therapies for those patients. A better understanding of outcomes in the real-world is, 
therefore, required. 
This introductory section presents my contribution to myeloma real-world research and to the 
optimisation of therapeutic outcomes of novel therapies used to treat this condition, through 6 
different retrospective real-world studies and one large systematic review. 
KP1 of 272 bortezomib patients demonstrated that cumulative dose ≥50mg is associated with 
improved efficacy outcomes. KP2 of 30 carfilzomib patients demonstrated that this therapy is 
efficacious and has a reasonably good tolerability profile (comparable to ENDEAVOR trial). 
The study also demonstrated how dose attenuation should be considered early on in elderly 
patients or those with cardiac morbidities, to improve tolerability. 
KP3 of 59 DTPACE patients demonstrated that this intensive cytotoxic chemotherapy can be 
beneficial in extending time to next treatment (TTNT) if consolidated with an autologous 
stem cell transplant (ASCT). Conversely, it appears to be of less benefit in non-ASCT-
eligible patients, or those more heavily pre-treated.  
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In KP4 which compared FDT (n=223) in the real-world to CT (n=253), FDT conferred 
inferior overall survival (OS), progression-free survival (PFS), and TTNT compared to CT. 
KP5 of 292 patients demonstrated that the median treatment-free interval (TFI) after 1
st
 line 
therapy was 6.9 months and declined with subsequent treatment phases. The same trend was 
observed in the different age and co-morbidity subgroups.  
The large systematic review of evidence of non-standard dosing of 78 different oral 
anticancer agents (KP6 and KP7) identified 34 papers eligible for inclusion, of which two 
were myeloma studies and showed limited evidence: one for thalidomide and one for 
lenalidomide. 
In KP8 which investigated infection-morbidity in 200 elderly myeloma patients, a number of 
baseline clinical predictors of infective episodes were identified, such as raised baseline 
lactate dehydrogenase (LDH) levels, chronic obstructive pulmonary disease (COPD) and 
smoking history. 
In summary, this introductory section will describe the real-world outcomes of myeloma 
patients treated with a number of novel agents and using different modalities. This thesis will 
discuss strategies/recommendations to optimise outcomes of those therapies, and to improve 
tolerability. 
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1. INTRODUCTION TO MULTIPLE MYELOMA: 
Multiple myeloma (MM) is a haematological malignancy of plasma cells (Bianchi et al 2014; 
Ramasamy et al 2015). It is caused by an uncontrolled proliferative behaviour of clonal B 
cells (Bianchi et al 2014; Ramasamy et al 2015). These cells secrete a dysfunctional 
monoclonal immunoglobulin or a fragment called paraprotein (Kyle et al 2009; Bianchi et al 
2014; Ramasamy et al 2015). Normal immunoglobulins are affected as a result, which 
predisposes patients to increased risk of infections (Bianchi et al 2014). In addition, the clonal 
cells displace the normal bone marrow causing a complex series of clinical symptoms such as 
anaemia, fatigue, bone resorption causing lytic lesions and/or fractures, hypercalcaemia, renal 
dysfunction, and neurological symptoms (Palumbo et al 2011; Bianchi et al 2014; Ramasamy 
et al 2015).  MM can also be non-secretory in some cases (Bianchi et al 2014; Ramasamy et 
al 2015).  
1.1. Epidemiology and risk factors: 
MM accounts for about 0.8% of all cancer types worldwide with 114000 new cases reported 
in 2012 (Ramasamy et al 2015; WCRFI 2016). In the UK, Cancer Research UK (CRUK) 
statistics reported annually around 5820 new diagnoses, which counts for 2% of all new 
cases, making it the 19th most common cancer (CRUK 2017). The number of myeloma 
reported deaths each year stands at 3000 (CRUK 2017). In 2013-2017, the 5-year and 10-year 
survival rates in England were 52.3% and 29.1% respectively (CRUK 2017).  
The precise aetiology of myeloma is unknown and the inherited risk remains to be fully 
understood, but a number of risk factors have been established (Ramasamy et al 2015). This 
includes old age, male sex, African or African-American ethnicity, genetics, and history of 
monoclonal gammopathy of undetermined significance (Ramasamy et al 2015; CRUK 2016). 
1.2. Diagnosis: 
Early diagnosis of myeloma is required in order to improve survival and clinical outcomes 
(Ramasamy et al 2015). A number of diagnostic tests are initially required during the first 
presentation with suspected myeloma (Dimopoulos et al 2011; Ramasamy et al 2015). These 
include a full blood count, bone, liver, and renal biochemistry profiles (albumin, calcium, 
creatinine and lactate dehydrogenase (LDH)), serum β² microglobulin, serum 
immunoglobulins (Igs), serum electrophoresis and immunofixation, and serum free light 
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chains (sFLCs) (Dimopoulos et al 2011; Ramasamy et al 2015). In addition, patients undergo 
a bone marrow aspiration and biopsy (Ramasamy et al 2015). Imaging is also used to screen 
and diagnose patients with skeletal surveys, CT and MRI scanning (Ramasamy et al 2015). 
1.3. Myeloma staging and risk stratification: 
Risk stratification of myeloma patients defines specific pathways of management, and helps 
to rationalise drug therapies (Chng et al 2014).  
The international staging system (ISS) for myeloma is a prognostic tool for myeloma patients. 
It combines serum β2 microglobulin and serum albumin to stage myeloma as I (Serum β2 
microglobulin <3.5 mg/L and serum albumin ≥ 3.5 g/dL) where median overall survival (OS) 
is 62 months, II (serum β2 microglobulin <3.5 mg/L but serum albumin <3.5 g/dL, or serum 
β2 microglobulin 3.5 – 5.5 mg/L irrespective of serum albumin) where median OS is 44 
months, and III (serum β2 microglobulin >5.5 mg/L) where median OS is 29 months 
(Ramasamy et al 2015). 
The detection of chromosomal abnormalities (CA) by fluorescent in situ hybridization (FISH) 
is an important factor which defines the biological features of myeloma at presentation.  For 
instance, in the newly diagnosed myeloma (NDMM) setting, high-risk disease presents with 
del (17p) and/or translocation t (4; 14), and/or translocation t (14; 16) and is associated with a 
median overall survival (OS) of 24.5 months (Palumbo et al 2015). However, standard-risk 
disease does not present with any of the chromosomal abnormalities previously mentioned, 
and is associated with a significantly higher OS of 50.5 months (P < 0.001) (Palumbo et al 
2015). 
Serum LDH is another key element in defining myeloma characteristics. Elevated LDH is an 
indicator of aggressive disease and/or a high proliferation rate, or extramedullary 
presentation, and is a predictor of poor prognosis (Dimopoulos et al 1991).  
Taking into account all of ISS, cytogenetics and serum LDH, the International Myeloma 
Working Group (IMWG) published a report which assessed pooled data from 4445 patients 
enrolled in 11 international clinical trials, based on which a simple and reliable tool named 
“revised ISS” or “R-ISS” was designed to help stratify myeloma patients at presentation with 
regard to the relative risk to their survival (Palumbo et al 2015). There are 3 categories in R-
ISS: category I (described as ISS stage I and standard-risk cytogenetics and normal LDH), 
category II (described as not I or III), and category III (described as ISS stage III and either 
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high-risk cytogenetics or high LDH) (Palumbo et al 2015). R-ISS has shown to be a simple 
and powerful prognostic staging system and is currently adopted in UK myeloma clinical 
practice.  
1.4. Therapeutic management of myeloma: 
MM remains an incurable disease with a relapsing and a remitting course. Newly diagnosed 
patients are treated with first line therapy to achieve a deep and durable response, but 
eventually relapse and start 2
nd
 and subsequent lines of therapy. 
Historically, MM is sensitive to many cytotoxic chemotherapy drugs such as alkylating 
agents (cyclophosphamide, melphalan), anthracyclines (e.g. doxorubicin), vinca-alkaloids 
(e.g. vincristine), and to corticosteroids (e.g. dexamethasone, prednisolone) (Kyle et al 2008). 
Treatment options have changed dramatically over the last two decades because of better 
disease understanding and major breakthroughs in therapeutics which revolutionised this field 
of haematology (Ramasamy et al 2015).  
New efficacious treatments from various pharmacological classes offer clinicians the ability 
to tailor treatments to individual patients, taking into consideration co-morbidities and the 
toxicity profile of individual drugs (Bianchi et al 2014). These include doublet to quadruplet 
combinations with different agents such as oral immunomodulatory drugs (IMiDs): 
thalidomide, lenalidomide and pomaliomide; proteasome inhibitors (PIs): subcutaneous 
bortezomib, intravenous carfilzomib and oral ixazomib, monoclonal antibodies 
(daratumumab, isatuximab) and histone deacetylase inhibitors (panobinostat).   
Starting treatment for NDMM is based on the assessment of clinical symptoms; particularly 
those suggestive of end organ damage (Ramasamy et al 2015).  IMWG-recommended 
assessment also includes histology and monoclonal protein quantification, as well as 
radiological identification of focal bone lesions (Ramasamy et al 2015).  
According to IMWG, active myeloma is defined as clonal bone marrow plasma cells >10% or 
biopsy-proven bony or extramedullary plasmacytoma plus one or more of the following four 
CRAB features which are regarded as evidence of myeloma-related end-organ damage: 
hypercalcemia: serum calcium >0.25 mmol/L (>1mg/dL) higher than the upper limit of 
normal or >2.75 mmol/L (>11mg/dL), renal insufficiency: creatinine clearance <40 mL per 
minute or serum creatinine >177mol/L (>2mg/dL), anaemia: haemoglobin value of >20g/L 
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below the lowest limit of normal, or a haemoglobin value <100g/L, and bone lesions: one or 
more osteolytic lesion on skeletal radiography, CT, or PET/CT (IMF, 2014). 
A diagnosis of active myeloma can also be made if any one or more of the following 
biomarkers of malignancy are present, referred to as the SLiM criteria: S: ≥ Sixty-percent 
(≥60%) clonal BM plasma cells; Li=serum free Light chain ratio involved: uninvolved ≥100; 
M: ≥1 focal lesion (≥5 mm each) detected by MRI studies (IMF, 2014). 
The decision on the most appropriate treatment for NDMM is governed by a variety of factors 
which include patient age, pre-existing co-morbidities, performance status (PS), ISS staging, 
cytogenetic risk, and transplant eligibility (Ramasamy et al 2015; WCRFI 2016).  
Standard of care splits patients into two sub-categories. Transplant-eligible (TE) patients are 
those younger (typically ≤65 years) fit patients and will receive an induction regimen, which 
is then consolidated with high dose chemotherapy and an autologous stem cell transplant 
(ASCT) (Ramasamy et al 2015). For those who are transplant non-eligible (TNE), 
management takes into account old age, PS, co-morbidities, and frailty; and consists of an 
appropriate treatment regimen, which can achieve the best response and maintains disease 
control (Ramasamy et al 2015). Across all pre-specified subgroups of NDMM patients, the 
use of maintenance lenalidomide (as demonstrated in Myeloma XI trial) was shown to 
significantly improve progression-free survival (PFS) (Jackson et al 2019). Upon future 
relapses, both TE and TNE patients are treated with a subsequent line of therapy. 
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2. IMPORTANCE OF REAL-WORLD DATA IN 
MYELOMA: 
Historically, patients diagnosed with active myeloma had a median OS of only around 3 
years, with limited treatment options available (Anderson et al 2016). In the past 15 years, we 
witnessed an increasing range of highly active treatment options being investigated in 
randomised clinical trials, offering novel doublet to quadruplet combinations and 
demonstrating significant improvements in myeloma disease responses and patients’ survival 
outcomes (D'Agostino et al 2019). As a result, the myeloma treatment landscape benefited 
from the incorporation of number of these novel agents/treatment regimen, which have 
become available in clinical practice as a result of safety and efficacy data demonstrated in a 
number of published large phase 3 randomised clinical trials. 
Real-world data, however, remains equally as important because it allows the myeloma 
community to understand the global variations in clinical practice, and to evaluate the 
outcomes of these therapies in the real-world. Clinical outcomes in routine care were 
previously reported to be inferior to what has been reported in the clinical trial setting (Chari 
et al 2017; Richardson et al 2018). The CONNECT-MM registry is a prospective 
observational registry of patients with NDMM in the US. From this registry, trial-ineligible 
patients demonstrated a significantly lower 3-year OS rate compared to their trial-eligible 
counterparts (63% vs 70%; p < 0.05) (Shah et al 2017). A prospective clinical cohort study 
from the German registry “Tumour Registry Lymphatic Neoplasms (TLN)” recruited 285 
non-transplant patients with NDMM at the start of frontline therapy and categorised 30% of 
those patients as trial-ineligible (Knauf et al 2018). Median PFS and OS in the trial-ineligible 
subgroup were inferior compared to the trial-eligible subgroup (Knauf et al 2018). 
 
The differences between clinical trials and the real-world in myeloma: 
The gap between therapy effectiveness in the real-world compared to safety and efficacy 
reported in clinical trial data lies in the characteristics that distinguish the two settings. The 
primary factor leading to this gap is the strict eligibility criteria to enrol patients in clinical 
trials; as demonstrated by the CONNECT-MM registry which reported that 40% of its 
patients were trial-ineligible (Shah et al 2017). This data was obtained by looking at common 
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exclusion criteria collected from 16 published myeloma clinical trials, then categorising 
patients in this registry according to their potential for trial eligibility.  The stringent selection 
criteria in clinical trials exclude a significant proportion of the real-world population.  
A US electronic health records (EHR) of 1265 real-world patients was retrospectively 
evaluated to identify representativeness of these patients (trial-eligible or ineligible) using 
eligibility criteria of 6 different hallmark randomised controlled trials (ASPIRE, 
TOURMALINE-MM1, ELOQUENT-2, POLLUX, CASTOR and ENDEAVOR) (Chari et al 
2020). The authors described a variation in the ineligibility rates for each individual trial, with 
up to 72.3% (range: 47.9%-72.3%) (Chari et al 2020). The authors also found that factors 
such as other malignancies, cardiovascular disease, acute infection, and renal impairment 
were the common reasons for trial ineligibility (Chari et al 2020). In addition, the study 
demonstrated that advanced age, Charlson comorbidity score of ≥2, later therapy lines (3-4), 
and refractoriness to the previous therapy were independently predictive of trial ineligibility 
(Chari et al 2020). In addition, the study reported that trial-ineligible patients had a 
significantly greater mortality risk (Chari et al 2020). Another study, from the Danish 
multiple myeloma registry, demonstrated that the majority of NDMM patients do not fulfil 
the inclusion criteria in phase 3 clinical trials (Klausen et al 2019).  
As a result, efficacy outcomes reported in the trial setting do not always translate into the 
real-world (Shah et al 2017). Patient-related factors which characterise real-world cohorts 
include advanced age, frailty, co-morbidities, organ dysfunction, poor performance status, 
advanced or aggressive/rapidly progressing disease. The latter are typical exclusion criteria 
from clinical trials, and this can drive the differences in safety and efficacy outcomes in 
routine care (Costa et al 2016; Shah et al 2017; Pulte et al 2018). 
In additions, patients from community centres are often under-represented because clinical 
trials tend to be open for recruitment mainly in regional/academic cancer centres. Besides, 
physicians in the trial setting are required to follow protocol-driven dose modification, which 
may lead to better tolerability and longer duration of therapy, compared to routine care.  
Patients in the real-world carry a higher toxicity burden from therapeutic interventions, 
particularly elderly patients or those with co-morbidities. Although we are observing a 
significant improvement in survival outcomes, a number of the novel and complex regimens 
currently in use can be associated with additional toxicity, which raises the new challenge of 
how to maintain patients on therapy, and how to achieve a high level of adherence. Besides, a 
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key difference between routine care and the clinical trial setting is that decisions about 
disease management strategies and therapy goals in clinical practice are mostly driven by 
patient’s and physician’s preference and motivation, as opposed to the strict adherence to the 
protocol, which is required in a clinical trial. For instance, the higher incidence of early 
treatment discontinuation in the real-world compared to clinical trials can be multifactorial, 
for reasons such as: patient mobility, distance from the treating institution, and the number of 
hospital visits involved in the delivery of myeloma therapy.   
Another key factor which can drive a difference in outcomes between the two settings lies in 
the significant variations between healthcare systems and clinical practices that exist across 
the world, and sometimes within an individual country. Moreover, a number of studies 
suggested that the decision to delay the initiation of therapy until a symptomatic relapse 
occurs (which is the practice we commonly observe in routine care) compared to starting 
therapy at the point of biochemical relapse, may be associated with inferior outcomes 
(Katodritou et al 2018; Lopez et al 2015). 
Understanding the difference in characteristics between the two settings helps to explain the 
difference in clinical outcomes for myeloma patients. But, equally as important is gaining an 
understanding of which elements are important from a patient’s perspective and which factors 
drive their treatment decision and their myeloma journey, to help researchers gain a greater 
understanding of the difference observed in outcomes. 
 
Understanding what is important for patients in the real-world: 
Patients in the real-world prioritise the need for a rapid control of system during the 
symptomatic presentation of the disease, because MM is associated with the highest symptom 
burden across all haematological malignancies (Johnsen et al 2009). Another important 
consideration is patients’ desire to achieve a good QoL by maintaining their activities of daily 
living. Impairment in QoL as a result of myeloma symptoms, treatment-related toxicities, or 
hospital inpatient admissions, can all adversely impact the treatment journey of patients and 
negatively affect their experience. 
Patients highly value a treatment option which is convenient. For instance, some patients 
prefer oral treatments over parenteral drug administration even with the knowledge about the 
inferior efficacy outcomes sometimes expected from this choice (Wilke et al 2018), because 
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they suffer from co-morbidities, or they have reduced mobility which affects their ability to 
attend hospital visits, or they prefer oral treatments because those have a minimal impact on 
their ability to go to work. 
Treatment-related toxicities can pose a significant burden to patients. Real-world datasets 
previously highlighted the impact of toxicities on the rate of treatment discontinuation in all 
myeloma settings (Jagannath et al 2016; Yong et al 2016). In addition, a reduced duration of 
therapy in the real-world because of toxicities can lead to inferior outcomes compared to 
phase 3 trial data.  
Moreover, as the management of myeloma is increasingly moving towards an individualised 
strategy empowered by patient choices, optimal efficacy outcomes and goals of therapy can 
mean different things to different patients. For instance, one patient may choose the 
continuous therapeutic strategy with a novel agent/regimen to achieved a long PFS, whereas 
another patient who highly values the treatment-free remission period to restore their QoL, 
may decide to discontinue therapy after a number of treatment cycles once a deep response is 
achieved, which in turn can confer different long term clinical outcomes. 
 
The importance of conducting real-world research described in this thesis: 
In order to address the gap in clinical outcomes between clinical trials and routine care and to 
support patients in routine care to experience a positive treatment journey, more real-world 
data are required on MM disease characteristics, treatment patterns and outcomes from 
unselected patients with advanced age and/or co-morbidities. In view of the importance of 
conducting real-world research in myeloma therapeutics and the need to understand current 
outcomes in the UK and devise strategies to optimise them in the future, I have performed a 
number of clinical studies in the era of novel agents.  
 I elected to describe eight of those studies in my PhD thesis. Each of these studies are 
discussed separately and will focus on literature review, rationale for study, brief description 
of results, in addition to the contribution of my research to the literature and the resulting 
changes in clinical practice.  
Three of the studies investigated outcomes of different therapeutic agents/regimen: 
bortezomib (KP1), carfilzomib (KP2) and DPACE (KP3). Two of the studies investigated 
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new treatment strategies: continuous vs. fixed-duration therapy (KP4) and treatment-free 
interval (KP5). Three of my research papers investigated how to improve tolerability of 
myeloma treatments in the real-world: systematic review protocol of non-standard dosing of 
oral treatments (KP6), the systematic review findings (KP7) and the infection-related 
morbidity study in elderly myeloma patients (KP8). 
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3. Optimising outcomes of myeloma therapies:  
3.1. Improving outcomes of bortezomib usage: 
3.1.1. Literature review and rationale of study: 
Bortezomib, the first-in-class proteasome inhibitor, remains a widely used anti-myeloma 
agent, despite licensing of newer agents. Its use in combination with other agents, is standard 
of care and is approved by the UK’s National Institute for Health and Care Excellence 
(NICE) to treat NDMM, in the TE setting (at 1.3mg/m
2 
twice weekly for up to 24 doses) in 
combination with dexamethasone as per IFM trial; or with dexamethasone and thalidomide, 
as per PETHEMA trial) (NICE 2014). Bortezomib is also NICE-approved to treat NDMM in 
the TNE setting (for a total of 51 doses) in combination with an alkylating agent (melphalan) 
and a corticosteroid (prednisolone), as per VISTA trial (NICE 2011). In the relapsed (RMM) 
setting, it is approved (for a maximum of 32 doses) in combination with dexamethasone as 
per APEX trial (NICE 2007). 
The influence of the route of bortezomib administration was investigated in a phase III 
multicentre study which randomised 222 RMM patients to either iv or sc bortezomib at 
1.3mg/m
2
 twice weekly for up to 8 cycles (Moreau et al 2011).The study showed that sc route 
offers non-inferior efficacy to iv (Moreau et al 2011). However, peripheral neuropathy (PN) 
was significantly less common in the sc arm compared to iv: any grade (G) was (38% vs. 
53%, p=0.044), G2≥ (24% vs.  41%, p=0.012), and G3≥ (6% vs. 16%, p=0.026) (Moreau et al 
2011).  
The influence of the frequency of bortezomib administration (once weekly vs. twice weekly) 
was investigated in a post-hoc analysis of a phase III trial (Bringhen et al 2010). This study 
showed that long term efficacy was similar between once and twice weekly bortezomib, and 
incidence of G 3/4 PN was significantly lower with weekly frequency (8% vs. 28%, p< .001) 
(Bringhen et al 2010). 
Based on the above data, clinical practice has adopted some changes in bortezomib usage to 
improve tolerability and optimise outcomes (e.g. dosing frequency from twice weekly to once 
weekly, choice of alkylating agent, and switching from iv to sc route to reduce PN). 
Along with my colleagues, I set out to study clinical outcomes of bortezomib in clinical 
practice both in the NDMM and RMM settings in a large cohort of patients treated within the 
regional Thames Valley Cancer Network (TVCN) in the UK. The aim was to assess factors 
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influencing efficacy outcomes. This work was published in PLOS ONE and the paper will be 
referred to herein as key publication 1 (KP1). 
3.1.2. Methodology: 
The study described in KP1 included adult patients with a diagnosis of symptomatic MM, 
treated between 2010 and 2016 with a bortezomib-based regimen for NDMM (first line 
therapy) or for RMM (therapy for relapse) (KP1). The study was approved by the regional 
Oxford University Hospitals NHS Foundation Trust across all TVCN participating sites. 
The chemotherapy prescribing database and the medical records of 272 patients were used to 
collect data on a number of patient, disease and treatment characteristics. Data on bortezomib 
adverse events (AEs) were not collected because the toxicity profile is well established from 
clinical studies. However, the proportion of patients discontinuing therapy due to AEs was 
recorded (KP1). Two main clinical outcomes were evaluated: OS and TTNT (KP1). 
We investigated the influence of the following factors on OS and TTNT: sex, age (<75 vs. ≥ 
75 years), ASCT, combination (doublet vs. triplet), cumulative bortezomib dose (<50mg vs. 
≥50mg), and route of administration (sc vs. iv) (KP1). We also conducted univariate (UVA) 
and multivariate (MVA) analyses (KP1). 
3.1.3. Key results: 
KP1 results demonstrated that in the total cohort of 272 patients, route of administration (iv 
vs. sc) influenced neither OS (p = 0.5), Fig (1A), nor TTNT (p = 0.052). Dose intensity 
analysis demonstrated that median OS was statistically longer in patients receiving a 
cumulative bortezomib dose of ≥50mg compared to <50mg (p = 0.003).  
In those who received <50mg (n=148), we performed further in-depth analysis and identified 
the following reasons for bortezomib discontinuation: treatment goal achieved (44%), 
intolerable toxicities (15%), disease progression (12%), death (16%), and unknown cause in 
the remainder (KP1). 
In the NDMM cohort, there was a trend for improved OS and TTNT with triplets compared to 
doublets but this was not statistically significant, Fig (1C). Administration of a higher 
cumulative dose (≥50mg) resulted in a longer median OS but without reaching a statistical 
significance, Fig (1D) (KP1). In the RMM cohort, triplets (compared to doublets) Fig (1E), 
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and a higher cumulative dose (Fig 1F) resulted in better OS but without statistical 
significance (KP1). When MVA Cox Regression analysis was performed, the following were 
identified as significant factors associated with improved OS: dose ≥50mg (p = 0.002) and 
ASCT (p = 0.002) (KP1). 
 
Figure (1): Outcomes of bortezomib therapies: A) OS in total cohort (sc vs. iv), B) OS in 
NDMM (doublet vs. triplet), C) TTNT in NDMM (doublet vs. triplet), D) OS in NDMM 
(≥50mg vs. <50mg), E) OS in RMM (doublet vs. triplet), F) OS in RMM (≥50mg vs. 
<50mg). (KP1). This figure is adapted from Figures 1-6 of (Djebbari et al 2018, PLOS ONE) 
under the open access license “CC-BY” (https://journals.plos.org/plosone/s/licenses-and-
copyright). The publisher confirms that no further permissions are required. 
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3.1.4. Impact of my research and future directions: 
This study examined bortezomib usage in clinical practice and helped provide information to 
myeloma clinicians, which can contribute to the optimisation of clinical outcomes. KP1 data 
reporting no difference in OS or TTNT according to route of administration (iv vs. sc) adds to 
the body of evidence (KP1). Evidence of similar bortezomib efficacy with either route has 
previously been published.  Similar response rates of these routes, in both NDMM and RMM 
settings, were reported in a large Czech retrospective study of 446 patients (Minarik et al 
2015). In addition, a large Italian study of 326 NDMM patients treated with VTD or VD, 
reported similar response rates (sc: 90% vs. iv: 80%, p=0.118) (Mangiacavalli et al 2017).  
KP1 established that cumulative bortezomib dose ≥50mg is associated with improved OS and 
a delayed need to start a subsequent therapy (KP1). This is the first study to look at 50mg as a 
cut-off value for cumulative dose, and we have justified in the paper why we opted for this 
cut-off value.  In clinical practice, patient could benefit from continuing bortezomib therapy 
to deliver a high cumulative dose (subject to tolerability) without early discontinuation, in 
order to deepen and/or extend myeloma response, and consequently improve outcomes. These 
findings add to the body of literature which suggested better OS according to cumulative 
dose. An analysis of 340 patient in VISTA trial who received bortezomib-based VMP therapy 
showed that median OS according to cumulative dose was (≥39mg/m2: 66.3 vs. < 39mg/m2: 
46.2 months, p < 0.0001) (Mateos et al 2015).    
KP1 also demonstrated that the impact of triplet vs. doublet on TTNT in either myeloma 
settings was modest, and the improvement in OS with triplets did not reach statistical 
significance (KP1). Although the strength of these findings is confounded by ASCT and 
cumulative bortezomib dose received, KP1 data is consistent with findings from the large 
phase III UPFRONT study which showed no difference in PFS between VD (doublet), VTD 
(triplet) and VMP (triplet), (14.7 vs. 15.4 vs. 17.3 months, respectively) (Niesvizky et al 
2015). 
The impact on local practice in TVCN has been large, as described in the testimonial 
(Appendix 2). In clinical practice, as a result of this work, clinicians continue bortezomib 
therapy for the maximum number of doses allowed by NICE, and do not discontinue therapy 
early when maximum response is achieved. Also, we tend to use more triplets because this 
was associated with a trend for better outcomes, despite the lack of statistical significance. 
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3.2. Improving carfilzomib outcomes: 
3.2.1. Literature review and rationale of study: 
Carfilzomib is a proteasome inhibitor, NICE-approved in 2017 to treat myeloma at first 
relapse (NICE 2017), as a result of data from ENDEAVOR trial which demonstrated 
improved median PFS of carfilzomib plus dexamethasone (CarDex) given twice-weekly, 
compared to bortezomib with dexamethasone (18.7 months vs. 9.4 months, p<0·0001) 
(Dimopoulos et al 2016).  
However, carfilzomib showed high cardiovascular adverse events (CVAEs): hypertension 
(G1-2: 16%; ≥G3: 9%), cardiac failure (CF; G1-2: 3%; ≥G3: 4.8%) and ischaemic heart 
disease (G1-2: 0.9%; ≥G3: 1.7 %), (Dimopoulos et al 2016).  Another trial (ARROW) 
investigated once weekly (70mg/m
2
) vs. twice-weekly (27mg/m
2
) dosing of carfilzomib 
(Moreau et al 2018). Median PFS was statistically in favour of once weekly carfilzomib (11.2 
vs 7.6 months; p=0.0029). However, ≥G3 AEs we observed in 68% and 62% of patients in 
the once vs twice-weekly arms, respectively (Moreau et al 2018). 
In view of the safety and efficacy data reported in ENDEAVOR and ARROW, carfilzomib 
dosing and frequency need to be further optimised. The European Myeloma Network (EMN) 
published a guidance document about the prevention, monitoring and management of cardiac 
toxicities induced by carfilzomib (Bringhen et al 2019). 
Myeloma clinicians need to further understand the tolerability and efficacy outcomes of this 
novel agent in the real-world, where patients often present with advanced age and/or co-
morbidities, and are under-represented in the large phase 3 trials. 
 In view of lack of real-world data on this subject, we conducted a study to investigate 
carfilzomib dosing, efficacy and toxicity outcomes in a cohort of myeloma patients treated 
with CarDex at first relapse, to understand outcomes of this therapy in the real-world and 
identify safe and efficacious dosing strategies. I designed and led this collaborative work for a 
period of 22 months (July 2017 to April 2019).  
This work was published in the British Journal of Haematology and the paper will be referred 
to herein as key publication 2 (KP2). 
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3.2.2. Methodology: 
The study was approved by the regional Oxford University Hospitals NHS Foundation Trust 
across all TVCN participating sites. I collected data on a number of patient, disease and 
treatment characteristics for a total of 30 patients. In particular, KP2 focused on highlighting 
history of pre-existing cardiac morbidities because there is a need to establish if carfilzomib 
can still be safely administered to some of those patients in the real-world; something that the 
main phase 3 carfilzomib trials did not investigate (KP2). 
Two main efficacy outcomes were evaluated: response rates and time to best response. I did 
not attempt to produce PFS and OS curves because the follow‐up period was too short for 
survival analysis of subgroups. In view of the current concerns of cardiovascular AEs of 
carfilzomib, it was important to review carfilzomib dosing schedules (full twice-weekly 
dosing or attenuated once weekly dosing), treatment duration and dose 
reductions/discontinuations (KP2). 
On reflection from my clinical practice as an independent prescriber in Oxford’s myeloma 
clinic and following on from discussions with fellow myeloma researchers across the UK, I 
looked at relative dose intensity (RDI) as an additional outcome measure, which has not been 
done before, and would be useful for clinicians in clinical practice (KP2). 
On reflection from KP1 where there was a lack of AE data analysis, KP2 focused on 
understanding all grade AEs, particularly cardiovascular AEs. The Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03 was used to collect data on AEs attributed 
to carfilzomib therapy (KP2). 
3.2.3. Key results: 
Out of a total of 30 patients eligible for inclusion, this real-world study identified 13 patients 
(43·3%) presenting with at least one pre‐existing cardiac morbidity, of whom 10 had 
hypertension (KP2). 
The overall response rate (ORR) was 92·6% (25/27). Median time to best response was 
75 days (range 30–210), i.e. after two to three cycles. This is very useful for clinicians and 
patients to be aware of, in order to manage treatment expectations (KP2). 
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KP2 identified variability in dosing across the cohort. Five patients received full twice‐
weekly dosing throughout, and six were dose‐reduced to weekly from the beginning. The 
remainder of the cohort (19/30 = 63·3%) received full dosing (56mg/m
2
 as per ENDEAVOR 
trial) for a number of cycles (1–12) and were then dose-reduced (to either 42 or 36 or 
27 mg/m
2
) or frequency-reduced  to weekly instead of twice weekly, or both (KP2). Main 
reasons for dose reductions were infections, hypertension, dyspnea, chest pain, history of GI 
perforation, fatigue, increase in baseline creatinine by nearly 50%, and diagnosis with a 
pulmonary embolism. Median RDI for the total cohort throughout the follow‐up period was 
67·4% (range: 26·6–100%) (KP2). 
Of a total of 60 AEs in the cohort (fully reported in the published paper), 16 were ≥G3, of 
which the most frequent were: anaemia, infections, hypertension, and PE. Of the 7 incidences 
of all grade hypertension, 4 were worsening pre‐existing hypertension (G1‐2) and 3 were new 
(one G2 and two G3) (KP2). 
3.2.4. Impact of my research and future directions: 
This study was the first to report real‐world outcomes of carfilzomib in the UK. To my 
knowledge, there are no published UK data describing myeloma outcomes in this particular 
setting.  KP2 demonstrated that carfilzomib in the real-world is an efficacious therapy, and 
resulted in a high ORR. KP2 also showed that carfilzomib has a reasonably good tolerability 
profile (total of 16 AEs of ≥G3) with a median relative dose intensity of 67.4%. For instance, 
≥G3 thrombocytopenia in this cohort was comparable to ENDEAVOR trial (10% vs. 8·4%), 
in addition to ≥G3 anaemia (13·3% vs. 14·5%), and ≥G3 hypertension (6·7% vs. 9%) (KP2).  
Moreover, KP2 demonstrated that caution should be applied in patients with cardiac co‐
morbidities, but the latter should not be a reason to exclude carfilzomib as a treatment option. 
However, and as per recent EMN guideline, risk assessment, comprehensive ongoing 
monitoring and proactive management of toxicities (with dose interruptions or delays or 
reductions) are required (KP2).  The impact on local practice was observed across TVCN, 
soon after the dissemination of these results at the regional “Update in Myeloma” evening. As 
described in the testimonial (Appendix 2), carfilzomib is now used more often, with caution 
but with more confidence since this data was published. Frequency of carfilzomib is reduced 
upfront if patients have a pre-existing cardiac morbidity or advanced age. 
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3.3. Improving outcomes of DPACE-based therapy: 
3.3.1. Literature review and rationale of study: 
Despite a significantly improved availability of novel agents to treat myeloma in the UK and 
the constantly changing myeloma therapeutic paradigm, some patients infrequently present 
with aggressive myeloma where the immediate use of novel agents is not the best option to 
quickly de-bulk the disease.  
The use of dexamethasone plus thalidomide in combination with a continuous infusion of 
cisplatin, doxorubicin, cyclophosphamide, and etoposide (DTPACE) is appropriate for those 
patients. It was first described in the relapsed setting and showed effectiveness as induction 
therapy before ASCT (Lee et al 2003). This intensive therapy is administered in hospital as an 
inpatient, where patients are admitted for a period of at least 5 days, and where cytotoxic 
chemotherapy is administered slowly but continuously over a period of 4 days in order to 
provide an optimal area under the curve (AUC) to maximally target myeloma cells, and also 
to reduce the risk of cardiotoxicity from doxorubicin. It is, however, associated with a high 
incidence of G3/4 toxicities.  
The addition of bortezomib to DTPACE (VTDPACE) led to improved outcomes (Barlogie et 
al 2007; Lakshman et al 2018). Historical indications for DPACE-based therapies include 
salvage treatment of aggressive MM, plasma cell leukaemia, and initial presentation with 
extra-medullary disease. Infusional chemotherapy continues to play a role, especially as a 
bridge to ASCT or as a method of rapid tumour de-bulking (Yuen et al 2018).  
 In the UK and in the era of novel therapies, variability in clinical decision-making amongst 
myeloma clinicians working at different hospitals led to the non-uniformity of UK practice 
regarding the use of DPACE-based chemotherapy. Therefore, we conducted a retrospective 
study in order to assess outcomes of the current indications of this therapy and to identify the 
optimal role for it within the evolving myeloma treatment landscape. This work was 
published in the European Journal of Haematology and the paper will be referred to herein as 
key publication 3 (KP3). 
3.3.2. Methodology: 
The cohort included patients treated with DTPACE, VTDPACE or VRDPACE from 2009 to 
2017. I set out to assess response rates, OS, TTNT for the total cohort and between 
subgroups, G3/4 haematological toxicities and treatment-related mortality (TRM) (KP3). The 
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study was approved by the regional Oxford University Hospitals NHS Foundation Trust 
across all participating sites. 
3.3.3. Key results: 
Given the rarity of use of this intensive chemotherapy in myeloma, it was a collaborative 
effort to find eligible patients making a cohort of 59 patients, which is the largest cohort 
reported in the UK to date. DPACE was used as 1
st
 line bridging to ASCT in 14 patients, and 
for relapsed disease in 45 patients. Choice of DPACE therapy was: DTPACE (39%), 
VTDPACE (35.6%), and VRDPACE (25.4%), Fig 2A. Median number of cycles received 
was 2 (1-4). ORR was 66.1%: sCR (23.7%), VGPR (11.9%) and PR (30.5%) (KP3). 
Median OS for the total cohort was 15.1 months, Fig 2B; and median TTNT was 14.2 
months, Fig 2C. Median TTNT (ASCT post-DPACE vs. no ASCT) was (12.8 vs. 2.7 months, 
p=0.118), Fig 2D. Median TTNT (months) according to number of prior therapies was (>2: 
5.1 vs. ≤2: 24.6, p=0.34), Fig 2E (KP3). 
After cycles 1 and 2 respectively, 49.1% and 40.7% of patients experienced at least one G3-4 
haematological toxicity; 64.4% and 44.1% required red blood cell (RBC) or platelet support. 
TRM rate was 10.5% (KP3). 
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Figure 2: A) Patient, disease and treatment characteristics, B) Overall survival (OS) in the 
total cohort, C) TTNT, D) TTNT (ASCT post-DPACE vs. no ASCT), E)TTNT according to 
number of prior therapies. This figure is obtained from Figure 1 of (Djebbari et al 2020, EJH) 
following approval and permission received from John Wiley and Sons and Copyright 
Clearance Center (https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=332737d9-d832-
453f-93c4-6dca1b1d348d) 
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3.3.4. Impact of my research, and future directions: 
This was the largest UK real-world analysis of DPACE therapy in myeloma. It showed that 
TRM rate was consistent with a study of 65 DCEP patients (10.5% vs. 9.7%) (Yuen et al 
2018). KP3 also demonstrated that DPACE can benefit patients by prolonging TTNT, only if 
consolidated with an ASCT afterwards. On the other hand, it had limited benefit in non-
ASCT-eligible patients, or those more heavily pre-treated (KP3). 
The impact of this work on local practice in TVCN and across the UK was notable, and is 
documented in the testimonial (Appendix 2).  This study changed practice and re-defined the 
subgroup of patients who benefit the most from this therapy. For patients who are non-ASCT-
eligible, results from KP3 suggest to consider scheduling a subsequent therapy shortly post-
DPACE, to maintain the achieved response or extend its duration, subject to tolerability and 
fitness for further treatment (KP3). 
My data proved that DPACE still has a place in the continuously changing myeloma 
treatment algorithms. This work helped to rationalise the use of this intensive therapy, and 
focus it on bridging to ASCT, or in relapsed disease which is not heavily pre-treated. Its use 
in any other settings has reduced.  
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4. OPTIMISING MYELOMA TREATMENT 
STRATEGIES: 
4.1. Continuous versus fixed-duration therapy: 
4.1.1. Literature review and rationale of study 
Prior to the novel agent era, treatment for TNE NDMM consisted of melphalan and 
prednisone (MP) given as fixed-duration therapy (FDT) followed by a treatment-free interval 
(TFI) until disease relapse. 
Today, standards of care in the UK consist of FDT using either a thalidomide-containing 
regimen in combination with an alkylating agent and a steroid, for instance: melphalan, 
prednisone, and thalidomide (MPT) or cyclophosphamide, thalidomide, and dexamethasone 
(CTD) or a bortezomib-containing regimen, i.e. bortezomib, melphalan, and prednisone 
(VMP) (NICE 2011)  Despite improved outcomes with FDT regimens, several studies have 
evaluated the impact of continuous and maintenance treatment approaches in both the TE and 
TNE NDMM settings.   
Lenalidomide, an oral derivative of thalidomide, has a different toxicity profile compared to 
its parent drug (SPC 2019). In the FIRST trial (Frontline Investigation of Revlimid and 
Dexamethasone versus Standard Thalidomide, MM-020), PFS and OS were significantly 
longer in TNE NDMM patients treated with lenalidomide and low-dose dexamethasone until 
disease progression (Rd continuous) compared with those treated with MPT given for a fixed 
duration of 72 weeks (Benboubker et al 2014). In addition, rates of G3-4 neutropenia, sensory 
PN were lower, and HRQoL related to treatment AEs was significantly better with Rd 
continuous compared with MPT (Benboubker et al 2014; Facon et al 2018). 
In UK clinical practice, CTD and bortezomib-based combinations, including VMP, are used 
more widely than MPT as FDT in patients with TNE NDMM.  Therefore, it is important to 
understand how Rd continuous treatment compares with the outcomes of patients with TNE 
NDMM in the UK real-world setting.  
As such, we conducted a case-matching TVCN-wide study in the TNE NDMM setting to 
compare outcomes of FDT, which is reflective of UK clinical practice, with those of Rd 
continuous from the MM-020 trial. This work was published in Leukemia & Lymphoma and 
the paper will be referred to herein as key publication 4 (KP4). 
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4.1.2. Methodology: 
This large study was conducted in collaboration with Celgene (a leading pharmaceutical 
company in malignant haematology, and manufacturer of lenalidomide) to compare efficacy 
outcomes of FDT (UK standard of care) with the continuous Rd arm of the FIRST trial, in the 
TNE NDMM setting (KP4). The study was approved by the regional Oxford University 
Hospitals NHS Foundation Trust  across all participating sites. 
To facilitate this comparison, case-matching and random sampling (according to 2 important 
prognostic factors for survival: age: ≤ 75 vs. > 75 years, and ISS Staging: I or II vs. III) were 
used to proportionally match a group of patients in the continuous Rd arm of FIRST trial to 
patients in the FDT cohort. The FDT cohort and the age- and ISS-matched Rd continuous 
cohort comprised 223 and 254 patients, respectively Fig 3 (KP4). 
 
 
Figure (3): Age- and ISS-matched FDT and Rd continuous cohorts (KP4). This figure is 
obtained from Figure 1S of (Sharpley et al 2020, Leukemia & Lymphoma) under the Creative 
Commons CC-BY-NC-ND license (https://creativecommons.org/licenses/), and following 
permission obtained from Taylor and Francis Online (https://www.tandfonline.com/ ) 
On reflection from my KP1, in which two main survival outcomes of bortezomib-based 
therapies (OS, and TTNT) were evaluated; it was important to investigate PFS as a 3
rd
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survival outcome in this study because it is a standard endpoint in phase 3 myeloma trials 
(KP4). 
4.1.3. Key results 
Study cohorts were: FDT (n=223) and Rd continuous cohort (n=254) (KP4). Median number 
of cycles received was 6 (range 1–28) in the FDT cohort and 19 (range 1–91) in the Rd 
continuous cohort. The most common frontline therapies in the FDT cohort were 
thalidomide-based regimens (66%) with a mean thalidomide daily dose of 51.4mg, and 
proteasome inhibitor-based regimens (24%) with a mean cumulative dose of bortezomib of 
4mg/m
2
 per cycle (KP4). 
 
This study demonstrated that the median OS with FDT was statistically inferior to Rd 
continuous: 30.3 vs. 58.6 months, HR 0.54, P < 0.0001) Fig (4A). Median PFS with FDT was 
also statistically inferior to Rd continuous (9.0 vs. 25.7, HR 0.37, P < 0.0001) Fig (4B). In the 
same way, this study demonstrated inferior median TTNT with FDT compared to Rd 
continuous (16.7 vs. 42.2, HR 0.38, P < 0.0001), Fig (4C) (KP4). 
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Figure (4): Comparison of survival outcomes (FDT vs. Rd continuous): A) OS, B) PFS, C) 
TTNT (KP4). This figure is obtained from Figure 1 of (Sharpley et al 2020, Leukemia & 
Lymphoma) and was used under the Creative Commons CC-BY-NC-ND license 
(https://creativecommons.org/licenses/), and following permission obtained from Taylor and 
Francis Online (https://www.tandfonline.com/) 
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4.1.4. Impact of my research, and future directions: 
This study demonstrated that using FDT strategy in the elderly TNE NDMM setting confers 
inferior OS, PFS, and TTNT than their age- and ISS-matched counterparts who were treated 
with Rd continuous treatment as part of the MM-020 trial (KP4). This data is consistent with 
other published studies that reported the benefits of continuous therapy in this setting 
(Palumbo et al 2014; Palumbo et al 2012). 
KP4 results were particularly supportive of the continuous therapy strategy for these patients, 
and added to the body of evidence because we performed a comparison of Rd continuous to 
UK-based FDT therapies (e.g. thalidomide-based: CTD, CTDa, and bortezomib-based: VD), 
which has not been done in the FIRST trial (only compared Rd continuous to thalidomide-
based MPT therapy) (Benboubker et al 2014). 
Since the completion of this work, NICE submission by Celgene for continuous lenalidomide 
plus dexamethasone in the TNE NDMM setting was successful, and this therapy has become 
available in the UK from June 2019 (NICE 2019). This offers patients and clinicians an 
additional treatment choice to use as frontline therapy, which is both safe and efficacious  
The work had a significant impact locally and nationally. Internationally, it was first 
presented at the American Society of Haematology (ASH) Conference in 2017, then at the 
European Haematology Association (EHA) Conference in 2018.  
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4.2. Treatment-free interval as a measure of efficacy: 
4.2.1. Literature review and rationale of study 
Up to 45% of new MM diagnoses in the UK are made in patients aged ≥75. Objectives of 
first-line treatment in elderly patients are disease control whilst maintaining HRQoL, which 
translates into improved survival (Mateos et al 2017).  
As the myeloma treatment landscape continues to be shaped, continuous therapy in the TNE 
NDMM setting has become the new standard of care. PFS advantage of continuous Rd was 
demonstrated in the MM015 trial and the FIRST trial (Benboubker et al 2014; Palumbo et al 
2014). Survival advantages of continuous daratumumab with VMP (D-VMP) and of 
continuous daratumumab with Rd (D-Rd) were recently demonstrated in ALCYONE and 
MAIA trials, respectively (Mateos et al 2018; Facon et al 2019). 
However, the decision to employ a continuous first-line strategy in routine practice requires a 
careful assessment of patients.  Achieving optimal outcomes in NDMM patients aged over 75 
years remains a considerable challenge for the myeloma community because of frailty and/or 
co-morbidities (Zweegman et al 2017). 
TFI in routine practice can occur if physicians and patients jointly decide to use FDT strategy 
and discontinue therapy after 4-8 cycles based on myeloma response achieved. Therapy can 
also be discontinued early as a result of significant toxicities. In both scenarios, TFI becomes 
very important for patients because it allows them to recover from toxicities and to restore a 
good QoL (KP5). TFI and good HRQoL have been described as additional measures of 
efficacy which can be employed to make individualised treatment decisions. A UK cross-
sectional survey of 370 myeloma patients demonstrated that being in a first TFI and 
experiencing a longer TFI were significantly associated with a better HRQL (Acaster et al 
2013). 
Before NICE approved continuous Rd in the TNE NDMM setting (NICE, 2019), FDT was 
the only standard of care with either a bortezomib-based or a thalidomide-based regimen, and 
remains a current option if lenalidomide is inappropriate.  
In view of the importance of TFI in the real-world, I conducted a large retrospective study to 
evaluate TFI as an additional metric of efficacy in routine practice, after 1
st
 and subsequent 
lines of therapy in elderly NDMM patients. The aim was to understand current practice and 
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identify strategies which can increase TFI and improve future outcomes. This work was 
published in PLOS One and the paper will be referred to herein as key publication 5 (KP5). 
4.2.2. Methodology: 
In a cohort of 292 patients, we set out to quantify TFI as a primary endpoint, after 1
st
 and 
subsequent lines of therapy in the total cohort and in the following subgroups: according to 
age (≤75 vs. >75 years) and co-morbidities as per Charlson Co-morbidity Index (CCI) score: 
(CCI: 0-2) vs. (CCI: 3-4) vs (CCI: ≥5) (KP5). The study was approved by the regional Oxford 
University Hospitals NHS Foundation Trust across all participating sites. 
I originally presented this data at the Annual American Society for Haematology (ASH) 
Conference in Dec 2017, during which I compared outcomes based on age and choice of first 
line therapy (bortezomib vs. thalidomide). I had discussions with a number of international 
collaborators and fed back to my research group in Oxford that it would more useful for the 
myeloma community to evaluate the influence of co-morbidities on outcomes instead of 
therapy choice.  
On reflection from this feedback, we decided to conduct further extensive work to collect co-
morbidity data, and perform further analyses of TFI and survival outcomes according to CCI.  
This resulted in stronger data and a more valuable research paper (KP5). 
4.2.3. Key results: 
The older cohort (>75 years) had a higher proportion of moderately to severely co-morbid 
patients compared to those ≤75 years (60% vs. 39%). Thalidomide was the most commonly 
used 1
st
 line therapy (61%), followed by bortezomib-based (22%), alkylator-based (10%), and 
lenalidomide (7%). The mean number of treatment cycles (6) was comparable between 
subgroups (KP5). 
Results in KP5 demonstrated that median TFI in the total cohort was longest after 1
st
 line 
therapy at 6.9 months, Fig (5A), and reduced after 2
nd
 line therapy to 1.8 months and after 3
rd
 
line therapy to 0.6 months. KP5 also showed that, in both age subgroups, TFI was also 
longest after 1
st
 line therapy, and decreased with increasing lines of therapy. In all co-
morbidity subgroups (CCI: 0-2, 3-4 and ≥5), TFI followed the same trend (KP5). 
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KP5 showed that older age (>75 years) confers significantly inferior OS (P<0.0001) Fig (5B), 
and PFS (P<0.01), Fig (5C), compared to ≤75 years. Patients experienced worse OS (P=0.01), 
Fig (5D), and worse PFS (p=0.025), Fig (5E), with increasing CCI scores (KP5). 
 
 
Figure (5): Treatment free interval and survival outcome: A) Waterfall plot of TFI following 
first-line therapy, B) OS by age (>75 vs. ≤75 years), C) PFS by age, D) OS by CCI (mild (0-
2) vs. moderate (3-4) vs. severe (≥5)), E) PFS by CCI, (KP5). This figure is adapted from 
Figures 1,4,5,6,7 of (Djebbari et al 2020, PLOS ONE) under the open access license “CC-
BY” (https://journals.plos.org/plosone/s/licenses-and-copyright). The publisher confirms that 
no further permissions are required. 
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4.2.4. Impact of my research, and future directions: 
This was the first and largest UK study to investigate TFI exclusively in the real-world 
elderly TNE NDMM setting, because this endpoint is yet to be adequately quantified, and 
appears to be of value to patients (KP5). 
This study demonstrated that median TFI in the total cohort was 6.9 months and declined 
with subsequent treatment phases. These results are consistent with data from a large 
international real-world study of myeloma patients, which showed that median TFI and time 
to progression decrease with increasing lines of therapy (Yong et al 2016). 
KP5 also demonstrated that a FDT approach for patients >75 years confers inferior PFS and 
OS compared to patients ≤75 years (KP5). This data is consistent with a number of subgroup 
analyses from large phase 3 trials in the TNE NDMM setting, such as FIRST, VISTA and 
ALCYONE trial (San Miguel et al 2008; Benboubker et al 2014; Mateos et al 2018).  
In addition, KP5 showed that survival outcomes shorten with increasing co-morbidity burden.  
This data is in line with a retrospective Japanese study which demonstrated that comorbidity 
burden and PS were predictive of outcomes in a cohort of patients ≥80 years of age (Matsue 
et al 2016).  
My work suggests that, where continuous therapy is not appropriate due to toxicities or 
patient choice, an effective FDT combination with good tolerability should be considered as a 
reasonable alternative approach, provided it contains novel agents (not limited to thalidomide 
or bortezomib). Future management can also consider possibly stopping lenalidomide after 18 
cycles if appropriate, because FIRST trial showed no OS benefit between continuous Rd and 
18 cycles of Rd (Benboubker et al 2014).  
Another key message from KP5 was: where a decision is made to use FDT instead of 
continuous therapy, the aim of therapy besides improving survival should be to maximise TFI 
which can, in turn, help improve HRQoL. The length of the resultant TFI from each therapy 
(until a myeloma relapse) should be viewed at as an additional indicator by which we can 
assess efficacy. As such, the title of paper was “TFI as an additional measure of efficacy” 
(KP5). 
The impact of my work on clinical practice, as described in the testimonial (Appendix 2) was 
to prompt clinicians to engage patients in the decision-making about continuous therapy 
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versus FDT which includes TFI. In order to help manage treatment expectations from 
clinicians and patients, this study quantified TFI and demonstrated that this efficacy endpoint 
is longest after 1
st
 line therapy, and declines significantly following subsequent lines of 
therapy; this is a useful data for NDMM patients who would prefer to opt for the FDT 
strategy followed by a TFI. In the relapsed setting, however, patients and clinicians may 
decide to opt for the continuous therapy strategy over FDT because TFI was shown to be very 
short with subsequent lines of therapy (KP5). 
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5. IMPROVING TOLERABILITY OF MYELOMA 
THERAPIES: 
5.1. Optimising dosing of oral myeloma therapies to improve tolerability: 
5.1.1. Literature review and rationale of study 
Some oral systemic anticancer therapies (SACT) are administered daily and continuously 
until disease progression or unacceptable toxicity (e.g. imatinib), and other agents are 
administered on specific days of a cycle followed by a break (e.g. lenalidomide), and some 
are administered for a specific number of treatment cycles then discontinued thereafter (e.g. 
thalidomide) (BNF, 2017).  Oral SACT can be associated with high-grade toxicities leading 
to dose interruption/delay, or treatment discontinuation. These AEs can also adversely affect 
HRQoL; treatment interruption or discontinuation may reduce treatment efficacy. 
 One approach to maintain patients on continuous oral SACT is to use non-standard dosing, 
where unlicensed doses/schedules are employed to improve tolerability, maintain HRQoL and 
continue therapy. This approach can be particularly useful for elderly and co-morbid 
myeloma patients taking oral agents such as: thalidomide, lenalidomide, pomalidomide, 
ixazomib or panobinostat. Official guidance on non-standard oral SACT dosing is non-
existent, and there is currently a gap in the literature on this subject. 
Therefore, I conducted a large systematic review to identify evidence of, and outcomes 
(efficacy, toxicity, HRQoL) from non-standard dosing of oral SACT in oncology and 
malignant haematology, in order to inform prescribing practices. In particular, it was 
important to identify the evidence in myeloma. 
Due to the enormity of this task, this work was published as two separate papers: the 
methodological protocol in the journal Systematic Reviews, and the findings in the journal 
BMC Cancer, which will be referred to herein as key publications 6 (KP6) and 7 (KP7), 
respectively. 
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5.1.2. Methodology: 
This large systematic review was conducted in accordance with the Preferred Reporting Items 
for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines (Moher et al 
2015) to identify evidence of non-standard dosing of oral SACT in cancer. It was registered 
on the PROSPERO database with the following ID: CRD42017076195 (KP6).  
Prior to conducting this review, I identified a gap in my learning as a junior researcher, and 
established the need to allocate time and resources to gain a good understanding of this 
research method. In July 2017, I enrolled in a week-long face-to-face systematic review 
course run by the University of Oxford, in which I learnt research methods used to design and 
conduct a systematic review, and how to report my findings.  
We intended for this piece of work to be very comprehensive, and to benefit not only 
myeloma clinical practice, but all tumor groups in oncology and malignant haematology 
However, I still had myeloma studies at heart and I was confident outcomes from the 
myeloma studies can be described separately, and findings can be shared with the myeloma 
community.  
A comprehensive search of 78 different oral SACT was performed in MEDLINE®, 
Embase®, Cochrane Library©, and Cumulative Index to Nursing and Allied Health 
Literature (CINAHL©) databases (KP6), followed by search expansion. The method is fully 
described in KP6. The authors worked together very closely to screen results, and appraise 
the quality of included studies, Fig (6) (KP7). 
As expected, this review was large, and identified 34 studies eligible for inclusion, of which 2 
were myeloma papers. I reported the findings in KP7, which discussed evidence of non-
standard dosing for all oral SACT drugs in the BNF, including myeloma drugs. 
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Figure (6): Flow diagram of search strategy and inclusion/exclusion (KP7). This figure is 
obtained from Figure 1 of (Djebbari et al 2018, BMC Cancer) under the Creative Commons 
Attribution license “CC-BY” (https://www.biomedcentral.com/about/policies/reprints-and-
permissions). The publisher confirms that no further permissions are required. 
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5.1.3. Key results: 
Of 5486 search results, 34 studies were eligible for inclusion, describing non-conventional 
dosing of oral SACT in oncology and in malignant haematology. Four studies were late phase 
clinical trials, 15 were cohort studies and 15 were case reports (KP7). 
The number of studies per drug investigated was as follows: sunitinib (10), imatinib (7), 
sorafenib (2), vemurafenib (3), dasatinib (2), lenalidomide (2), crizotinib (2), erlotinib (2), 
gefitinib (2), temozolomide (1) and thalidomide (1). Dose interruption strategies were the 
most common (14 studies), followed by dose reductions (9 studies), and other dosing 
strategies (11 studies) (KP7).  
Of all 34 studies, two reported non-standard dosing in myeloma: one of thalidomide and of 
lenalidomide (KP7). 
The thalidomide study was a small randomised trial of 23 myeloma patients, and investigated 
efficacy and AEs of a one-week interruption of thalidomide following daily administration 
for 3 weeks, compared to continuous therapy (Mangiacavalli et al 2012). The study was rated 
of a (moderate to high) quality. The study reported worse OS (p < 0.001) and PFS (p = 0.02) 
in the intermittent arm compared to the continuous arm. However, there was no difference in 
peripheral neuropathy (PN). A drawback of this study was the very small number of patients 
(≤30) (Mangiacavalli et al 2012). 
The lenalidomide study was a small prospective single arm myeloma cohort study. It aimed to 
evaluate efficacy and cost-saving of alternate-day dosing of lenalidomide (25mg every other 
day for 21 days then 1 week break) (Popat et al 2014). The study was rated of a (moderate to 
low) quality. Median duration was 12 cycles. Median PFS and OS were 11.5 months and 
36.5 months, respectively. Cost-savings were £19,408.43 per patient compared to standard 
daily dosing (Popat et al 2014).  A Drawback of the study was the lack of toxicity and 
HRQoL data. Authors of this paper suggest exploring this strategy in a larger cohort of 
patients. 
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5.1.4. Impact  of my research, and future directions: 
I demonstrated my commitment to go to great lengths to identify much needed evidence of 
non-standard dosing of all oral SACT (78 agents as of 2017) used in oncology and non-
malignant haematology (KP6, KP7). This is very helpful to all cancer clinicians (Oncologists 
and Haematologists alike) who will inevitably face scenarios in daily practice where non-
standard prescribing is the only remaining option, prior to permanently discontinuing therapy 
due to intolerable toxicities.  
I demonstrated acquisition of good research skills by conducting this large piece work, 
particularly using a robust methodology (KP6). In addition, I demonstrated my ability to 
appraise and synthesise findings of this work, which was published as a separate paper in 
BMC Cancer (KP7). 
KP6 and KP7 describe the first comprehensive systematic review to tackle this question for 
all oral anti-cancer agents. Two thirds of all included studies related to solid tumors, whilst 
only a third discussed haematological malignancies (KP7). 
The primary objective of this systematic review was fully met, by identifying and 
categorising key non-standard dosing strategies, which were: dose reductions, dose 
interruptions and others (e.g. alternate day dosing).  
In terms of drugs used to treat myeloma, we found limited evidence of non-standard dosing 
(one small sample size clinical trial of thalidomide, and one small prospective lenalidomide 
cohort study). Limitations of these studies do not allow generalisability of results in clinical 
practice, but warrant further investigation in large late phase prospective clinical trials. 
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5.2. Infections-related morbidity and clinical predictors: 
5.2.1. Literature review and rationale of study: 
Infections cause significant morbidity and mortality in myeloma (Augustson et al 2005). The 
risk is increased by immunoparesis and immunosuppressive therapy (Teh et al 2014). The 
nature and patterns of infections has evolved over time, because of the continuously changing 
myeloma treatment paradigm, which uses a range of systemic therapies from distinct 
pharmacological classes and with different toxicity profiles. 
The aim of first line therapy in TNE NDMM patients is to achieve an optimal disease control 
and to achieve a good HRQoL (Mateos et al 2017). Infections can directly affect HRQoL, and 
treatment interruptions due to infection-related morbidity can lead to sub-optimal myeloma 
responses. 
Therefore, it is crucial to understand myeloma infections in the real-world in order to reduce 
the impact of this complex problem on the patient’s treatment journey, particularly in view of 
advanced age or co-morbidities, and also in view of the recent UK approval of continuous 
lenalidomide in this setting.  
We performed a large retrospective real-world study of 200 consecutive TNE NDMM 
patients treated with UK standard of care (2009-2018) to establish infection morbidity and 
mortality over a 12 month period from diagnosis, in addition to identifying clinical predictors 
of infective episodes. 
To my knowledge, there are no published UK routine care data investigating all these 
outcomes and predictors, particularly in elderly co-morbid patients who are largely under-
represented in myeloma clinical trials. This work was published in Haematologica and the 
paper will be referred to herein as key publication 8 (KP8). 
5.2.2. Methodology: 
A total of 200 consecutive TNE NDMM patients treated with UK standard of care (2009-
2018) (KP8) were included. The study was approved by the Oxford University Hospitals 
NHS Foundation Trust. 
Data were collected on a number of infections outcomes over a 12 month period.  UVA and 
MVA analyses were performed to identify patient, disease, and treatment-related factors 
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associated with increased incidence of all grade infections, incidence of ≥G3 infections, and 
infection-related hospitalisation (KP8).  
5.2.3. Key results: 
Over the first 12 months from diagnosis in a total cohort of 200 patients, 116 documented 
infections were identified, of which 72 were ≥G3. Cumulative incidence of first all grade, and 
≥G3 infections were 33% and 22%, respectively. Two-thirds of infections occurred in the first 
6 months. Fifty six episodes required a significant inpatient stay (>3 days) (KP8).  
Using UVA of cumulative incidence of all grade and high grade infections, KP8 showed that 
elevated LDH, COPD, and smoking were associated with a significantly higher infection 
incidence Fig (6A-F). (KP8).  
By MVA Poisson regression, elevated baseline LDH and smoking predicted for higher all 
grade infection rate, whilst receiving a higher number of treatment cycles (≥6) was associated 
with a reduced infection rate (KP8).  
 For high grade infections, this study demonstrated that elevated LDH and smoking predicted 
for a higher risk of infections, whilst receiving a higher number of treatment cycles and 
achieving a deep haematological response appeared to have a protective effect (KP8). 
Elevated LDH and smoking were independently associated with a higher risk of prolonged 
infection-related hospital admissions, whereas a deep response appeared to have a protective 
effect (KP8).  
The landmark analysis revealed that median OS was shorter for patients who experienced 
infections in the first 6 months compared to those who did not. This was demonstrable for all 
grade infections (p=0.0838) as well as high grade infections (p=0.0176) (KP8).  
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Figure (7): Cumulative incidence curses of infections: A) Cumulative incidence curves of all 
infections according to elevated LDH, B) Cumulative incidence curves of ≥G3 infections 
according to elevated LDH, C) Cumulative incidence curves of all infections according to 
COPD, D) Cumulative incidence curves of ≥G3 infections according to COPD, E) 
Cumulative incidence curves of all infections according to smoking, F) Cumulative incidence 
curves of ≥G3 infections according to smoking (KP8). This figure is obtained from Figure 1 
of (Djebbari et al 2020, Haematologica), accessed from Haematologica Journal website 
(http://www.haematologica.org). Permission to re-use Figure 1 was obtained from Ferrata 
Storti Foundation. 
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5.2.4. Impact of my research, and future directions: 
Managing infections associated with novel therapies has become a high priority for the 
myeloma community in recent years, as survival in this incurable cancer continues to 
improve. KP8 investigated the complexity of infections in elderly myeloma patients, and is 
the first study to assess the influence of an extensive number of patient, disease and treatment 
characteristics on infection occurrence, which can help clinicians in the early identification of 
high risk patients (KP8).  
Cumulative incidence of all grade infections reported in KP8 (33%) is consistent with a 
combined analysis of 476 patients from two large NDMM trials (33.2%) (Offidani et al 
2015). In contrast, the figure for ≥G3 infections (22%) was significantly higher than trial 
patients (11%), possibly as result of advanced age and co-morbidities in this real-world 
cohort of patients, most of whom would be trial-ineligible (KP8). 
KP8 identified clinical predictors of infections and of infection-related hospitalisation. All 
these findings are helpful for clinicians to highlight at-risk groups (KP8). 
Results described in KP8 are consistent with an analysis of the FIRST trial in TNE NDMM, 
where elevated LDH was retained in the definition of ≥G3 infections according to a validated 
prediction model (Dumontet et al 2018). KP8 results are also consistent with an Australian 
study of 199 patients which found no independent association between infections and the 
choice of therapy (IMiD vs. PI) (Teh et al 2015). 
In light of all these data, we issued recommendations regarding baseline infection risk 
stratification of patients, using the predictors we identified.  
TEAMM trial demonstrated that the prophylactic use of 12 weeks of levofloxacin 500mg 
daily for myeloma patients receiving therapy significantly reduced febrile episodes and deaths 
without increasing healthcare associated infections (Drayson et al 2019). Therefore, KP8 
recommended instituting primary antibacterial prophylaxis for at-risk patients, or for those 
with a history of recurrent respiratory tract infections (KP8). 
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6. CONCLUDING REMARKS: 
Myeloma remains an incurable cancer with a relapsing and a remitting course, but it has 
become increasingly more treatable (Ramasamy et al 2015).  My journey in this field as a 
haematology pharmacist, independent prescriber in Oxford’s myeloma clinic and as a 
researcher, has been quite challenging but very exciting because the therapeutic management 
of this condition witnessed a major revolution in the last decade particularly with the advent 
of novel agents from distinct pharmacological classes such as proteasome inhibitors (e.g. 
bortezomib, carfilzomib, ixazomib), newer immunomodulatory drugs (e.g. lenalidomide and 
pomalidomide) and CD38 monoclonal antibodies (daratumumab). Conducting real-world 
research in this area of therapeutics is absolutely paramount because clinical outcomes 
reported in clinical trials are not always replicated in routine care (Richardson et al 2018).  
Real-world data in myeloma is a powerful platform which helps to understand outcomes in 
clinical practice. I embarked on a journey to address a number of questions which emerged 
from the increased usage of myeloma novel agents in routine care. My real-world research 
projects enabled a better understanding of how the use of a number of therapeutic agents and 
strategies can be optimised to improve clinical outcomes, particularly in elderly or frail 
patients or those with co-morbidities. In this introductory section, I selected eight key 
publications and demonstrated my contribution to the myeloma field with one key aim: 
optimising therapeutic outcomes whilst improving tolerability.   
On the basis of the data demonstrated in the 6 retrospective studies and the large systematic 
review, a number of conclusions can be drawn. Bortezomib therapy remains a pillar in 
myeloma treatment. A cumulative bortezomib dose ≥50mg is associated with improved 
efficacy outcomes (OS and TTNT) (KP1). The use of triplets over doublet combinations can 
improve outcomes but this was not shown to be significant (KP1). 
Carfilzomib therapy is efficacious and reasonably well tolerated despite old age and co-
morbidities which characterise our real-world cohort (KP2). In the latter subgroup, a key 
strategy to maintain therapy and limit toxicity is to employ dose reductions early on during 
the course of treatment or upfront where necessary (KP2). In future, it would be important to 
investigate outcomes of a larger cohort to measure the extent of changes in practice based on 
our data, and if our results are replicated in other treatment centres. 
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The intensive cytotoxic chemotherapy DPACE still has a place in the era of myeloma novel 
therapies. However, KP3 demonstrated that this regimen can only be beneficial in extending 
TTNT if consolidated with an ASCT (KP3). On the other hand, it achieves a less than 
desirable outcome in non-ASCT-eligible patients, or those more heavily pre-treated (KP3).  
The continuous therapy strategy in elderly TNE NDMM patients offered a significantly 
improved OS, PFS and TTNT, compared to FDT strategy where thalidomide is largely used 
(KP4). However, a future study can investigate the same comparison but where the FDT 
cohort is treated with bortezomib, a current standard of care in this is setting and a more novel 
agent than thalidomide.  
TFI in elderly myeloma patients was shown to be longest after 1
st
 line therapy (median=6.9 
months) and declined with subsequent lines of therapy (KP5). This was also demonstrable 
across the different age and co-morbidity subgroups. In the future, we suggest to myeloma 
clinicians as well as research investigators to consider the TFI as an additional measure of 
efficacy in clinical practice, and as an exploratory endpoint in prospective clinical trials 
(KP5).  
Evidence of non-standard dosing of oral anticancer agents in oncology and haematology was 
identified in 34 studies. The evidence for myeloma drugs was very limited (2 studies of 
moderate quality) (KP6, KP7). 
Infections in elderly NDMM patients continue to pose a significant problem which is very 
complex to prevent or limit during the course of myeloma treatment (KP8). Baseline infection 
risk stratification needs to be employed by clinicians prior to starting therapy, using the 
clinical predictors identified in this study (KP8). In future, infection outcomes need to be re-
evaluated to assess the role of the proposed risk stratification system. In addition, the 
prophylactic use of 12 weeks of levofloxacin 500mg daily for current myeloma patients 
receiving therapy (as per TEAMM trial) is strongly recommended (Drayson et al 2019).  In 
view of the ongoing COVID-19 pandemic, it would also be important to assess infection 
outcomes in myeloma patients who contracted SARS-Cov-2, in addition to the impact of the 
recent changes to standard of care during the pandemic. 
The methodologies described in this body of work had a number of advantages which helped 
me meet my objectives of answering some urgent research questions. Retrospective study 
design enables the assessment of a large myeloma cohort (e.g. n=272 in KP1, n=223 in KP4, 
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n=292 in KP5, and n=200 in KP8) conveniently using the electronic chemotherapy 
prescribing as well as patient records. As the lead investigator, I had the independence to 
explore all available patient/disease/treatment data in order to answer urgent or complex 
clinical questions which are encountered in clinical practice (e.g. conducting extensive data 
collection to enable UVA and MVA analyses to identify baseline characteristics associated 
with increased risk of myeloma infections, KP8).  
The retrospective analysis of data about myeloma patients previously exposed to a given 
treatment choice or strategy represents an additional research platform to improve the 
understanding of these therapies in elderly patients with co-morbidities, who are largely 
under-represented in prospective phase 3 myeloma trials. This filled gaps in the literature. 
My myeloma studies presented with a number of limitations which include their retrospective 
(less powerful than prospective studies), non-randomised nature, patient selection bias, under-
reported toxicities and missing data. The small sample size was another limitation in the 
carfilzomib study (n=30) (KP2). In all of my real-world studies, I acknowledged all the 
limitations in the discussion sections of the published papers.  
Specific limitations of each of the individual studies are as follows: KP1 (lack of AE data, 
lack of subgroup analyses according to cytogenetics, lack of frailty and co-morbidity data), 
KP2 (small sample size, and lack of KM survival curves for OS and PFS due to short follow 
up), KP3 (lack of complete AE data, lack of complete cytogenetics data, inability to conduct 
survival comparisons for OS and TTNT according to the choice DPACE, i.e. DTPACE vs. 
VTDPACE vs. VRDPACE), KP4 (a clinical trial cohort vs. a real-world cohort is not an ideal 
comparison, lack of co-morbidity, frailty, cytogenetic and AE data in the real-world cohort), 
KP5 (lack of AE data and cytogenetic data, lack of subgroup analysis according to R-ISS), 
KP6+KP7 (lack of reporting of full data from eligible papers in the systematic review, i.e. 
efficacy, AEs and QoL), and KP8 (risk of under-reporting/under-documentation of infective 
episodes in this retrospective dataset, and lack of complete cause of death data). 
Real-world data continues to play an important role in improving clinical outcomes of 
myeloma patients. In view of the continuously changing myeloma treatment paradigm which 
will continue to recruit newer agents currently investigated or recently reported in clinical 
trials (e.g. isatuximab, selinexor, and belantamab), research questions originating from 
routine care will continue to be raised and will need to be addressed.  
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We need to continue to interrogate real-world myeloma data in the future in order to identify 
answers to pertinent therapeutic questions. I plan to address a number of research questions 
following the completion of my PhD. The safety and efficacy of the novel BCMA antibody-
drug-conjugate belantamab need to be evaluated in the relapsed/refractory myeloma setting 
where this drug has recently been made available as part of a GSK compassionate use 
scheme. There is currently no real-world data describing myeloma outcomes with this novel 
class of therapeutics. In addition, isatuximab is a newer CD38 monoclonal antibody which 
demonstrated its efficacy and safety in combination with pomalidomide and dexamethasone 
(IsaPomDex) in the relapsed/refractory myeloma setting in a large phase 3 trial (Attal et al 
2019). However, there is no data to describe outcomes in the real-world. I plan to investigate 
those outcomes nationally across the UK by recruiting all patients enrolled in the IsaPomDex 
compassionate use scheme offered by Sanofi.  
In order to improve the quality of these 2 studies,  I plan to modify some aspects of my 
methodology by: collaborating with investigators nationally (across the UK) instead of locally 
(Oxford) or regionally (Thames Valley) in order to maximise the sample size; performing 
data collection during the active management of the patient  instead of after treatment 
completion (to reduce the risk of data misinterpretation and the amount of missing data); 
investigating adverse events in more depth; and conducting subgroup efficacy analyses 
(according to cytogenetics, age, and co-morbidities). Because myeloma is a disease of the 
elderly, I would like for all my future real-world studies to include a frailty and QoL 
assessment at baseline, during and at the end of therapy. 
In summary to date, my research journey in the field of myeloma therapeutics  has been full 
of challenges but it represented a significant learning curve, during which I developed my 
research skills and methods, and succeeded in leading a number of large cohort studies, and in 
collaborating with other myeloma researchers.  
I achieved a good understanding of the conduct, methods and interpretation of real-world 
data. I have also demonstrated competence in conducting high quality literature research 
through my systematic review. I gained experience in leadership and management because I 
completed and published all my research studies I performed to date. Through my key 
publications, I answered a number of urgent clinical questions originating from clinical 
practice, and changed practice locally, regionally and nationally. I gained good experience in 
disseminating my research data in national, European and international haematology 
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conferences. I am also very experienced at of writing up my research findings and submitting 
to haematology journals, and responding to questions arising during the peer-review process. 
My experience to date with real-world research places me in a favourable position to continue 
to expand my myeloma research portfolio. 
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8. APPENDIX 1: OTHER PUBLICATIONS NOT 
INCLUDED IN THIS THESIS 
 
In addition to the key publications (KP) used in this introductory section, I have contributed 
to a number of other published papers (listed below) in prestigious peer-reviewed journals, 
both in myeloma and lymphoma, either as Lead author or significantly contributing author. I 
refer to them as other publications (OP) 1-12. I have also described briefly 3 of the most 
influential lymphoma papers: 
 
 OP1:Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora 
SM, Hatton CSR, Collins GP, Eyre TA. Efficacy of R-GCVP in patients with late relapse of 
diffuse large B-cell lymphoma. Br J Haematol. 2019;186(6):191-195.  
I led this TVCN-wide UK multicentre study to investigate the efficacy and safety of R-GCVP 
(rituximab with gemcitabine, cyclophosphamide, vincristine and prednisolone) in patients 
with diffuse large B-cell lymphoma (DLBCL) presenting with late relapse (Djebbari et al 
2019). This treatment is often only used as first line in patients with cardiac co-morbidities 
who cannot receive anthracyclines (doxorubicin) as part of R-CHOP (rituximab with 
doxorubicin, cyclophosphamide, vincristine and prednisolone) (Fields et al 2014). The 
rationale for the study is the absence of data on what is the best treatment for late relapse in 
patients who previously received R-CHOP as first line therapy and cannot receive it again at 
relapse. I focused on response rates, OS and PFS, in addition to toxicity outcomes. My study 
demonstrated that R‐GCVP was a reasonably well tolerated treatment strategy with proven 
efficacy in an elderly cohort of patients with late DLBCL relapse. The AE profile of this 
therapy was similar to what was observed in the original R‐GCVP trial (Fields et al 2014) 
(OP1). 
 My R-GCVP study was the first to describe outcomes of this therapy for patients with 
DLBCL presenting with late relapse. Response rates were quite high. However, I did not find 
differential responses or survival according to prior rituximab exposure or length of first 
remission. This finding requires further evaluation in large prospective studies. This study is 
useful for lymphoma clinicians across the world, if they encounter a scenario of late DLBCL 
relapse (previously treated with R-CHOP) with the new knowledge from my study, showing 
that R-GCVP is a clinically robust option for this indication. 
I contributed towards the study methodology (data parameters to be collected). I contributed 
to data collection and co-ordinated the study with other UK participating centres. I performed 
data analysis in Tables (baseline characteristics and toxicity tables). I led on writing the 
manuscript. I estimate my total contribution at 40-50%.  
 
 OP2: Eyre TA, Djebbari F, Kirkwood AA, Collins GP. A systematic review of the efficacy 
of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell 
lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era. 
Haematologica. Epub: 2019 Sep 5.PMID: 31488560 
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I made a significant contribution to this game-changing lymphoma systematic review on the 
efficacy of central nervous system (CNS) prophylaxis with stand-alone intrathecal (IT) 
chemotherapy in DLBCL patients treated with anthracycline-based chemotherapy in the 
rituximab era (Eyre et al 2019A). In recognition of my previous success at conducting a large 
systematic review, the lymphoma research team nominated me to lead on the search strategy 
for this review, in order obtains a timely answer to this urgent clinical question.  
CNS relapse of DLBCL remains uncommon but a very poor outcome. The efficacy of stand-
alone IT prophylaxis in preventing/reducing CNS relapse remains unclear. No systematic 
review has attempted to answer this question in the era of anti-CD20 monoclonal antibody 
(mab) therapy. I conducted a systematic and comprehensive search (2002-2019) using Ovid 
MEDLINE®, Ovid EMBASE® and Cochrane Central Register of Controlled Trials. Out of a 
total of 804 results screened using a careful inclusion and exclusion criteria, 14 studies were 
eligible for inclusion: 3 post hoc analyses, 1 prospective and 10 retrospective series (Eyre et 
al 2019A).  
 I found no evidence of benefit for IT prophylaxis in preventing CNS relapse in DLBCL in 
the rituximab era (Eyre et al 2019A). My systematic review was highly valued by expert 
reviewers in the journal Haematologica, and by the lymphoma community after publication of 
the paper. This led to a change in practice in TVCN and other parts of the UK, by limiting the 
use of IT MTX in DLBCL only to carefully selected patients. 
I contributed towards the conception and design of this systematic review. I conducted the 
full search strategy and obtained the results. I contributed towards the inclusion/exclusion of 
studies, but not to quality appraisal. I contributed to the manuscript by writing the methods 
section, and by leading on submission to Haematologica.  I estimate my total contribution to 
this project to be 40-50%.  
 
 OP3: Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, 
Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, 
Collins GP, Hatton CSR. Impact of intended and relative dose intensity of R-CHOP in a 
large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with 
curative intent: no difference in cumulative incidence of relapse comparing patients by age. J 
Intern Med. 2019; 285(6):681-692.  
I was a collaborator on this very large (n=790) UK-wide study of dose intensity of R-CHOP 
in elderly patients treated for DLBCL. The rationale for the study is that co-morbidities and 
frailty in older patients often contribute to treatment-related toxicities, which place a burden 
on the healthcare setting. Better dosing strategies are required to treat older patients whilst 
maintaining tolerability (Eyre et al 2019B) 
This study examined the influence of intended and relative dose intensities (IDI and RDI) of 
the doxorubicin and cyclophosphamide components of R-CHOP, in addition to influence of 
age and co-morbidities, on clinical outcomes (Eyre et al 2019B).  
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The study demonstrated that PFS and OS were significantly inferior in patients ≥80 vs. 70–79 
years (P < 0.001). In patients aged 70–79 years, PFS and OS were longer (P < 0.001) with IDI 
≥80% compared to IDI < 80%. However, in patients ≥80 years, there was no difference in 
PFS (P = 0.88) or OS (P = 0.75) according to IDI. MVA showed that cumulative incidence of 
relapse in patients aged 70-79 was higher if IDI <80% was used (P=0.04), but using different 
IDIs in the older subgroup showed no difference (P=0.32) (Eyre et al 2019B). 
This was the largest real-world clinical study I have been involved in (n=790). It reported 
very strong data arguing in favor of the use of attenuated R-CHOP dosing (i.e. R-mini-
CHOP) to provide sufficient efficacy, and should be considered as a reasonable alternative 
approach to treat patients ≥80 years, with curative intent (Eyre et al 2019B).  Practice across 
the UK started to implement this approach in treating older patients (R-mini-CHOP is the 
new standard of care in patients ≥ 80 years).  
I contributed towards data collection: dose intensity of doxorubicin and cyclophosphamide 
for Oxford patients, the choice of CNS prophylaxis (intrathecal or IV) in addition to preparing 
dose intensity of vincristine in case requested by reviewers. I contributed towards the review 
of the manuscript. I led on the submission of the written manuscript to the Journal of Internal 
Medicine on behalf of the first other. I estimate my total contribution to be at least 5%.  
 OP4: Djebbari F, Tatarczuch M, Panitsas F, Vallance G, Sultanova M, Kothari J, Ramasamy 
K, Peniket A. Resource implications of bortezomib therapy in a large UK cohort: An 
evaluation study. J Oncol Pharm Pract. 2019; 25(8):1995-1998 
This work was originally led by Dr Tatarczuch but I took the lead role after he moved back to 
Australia. I contributed towards data and to the interpretation of findings. I led on writing the 
manuscript, submission and publication of the paper, and I prepared the full responses to 
questions raised by peer reviewers. I estimate my total contribution at 30% 
 OP5: Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, Rabin N, Kothari J, 
Alchi B, Haynes R, Winearls C, Roberts I, Ramasamy K. Long term outcomes in monoclonal 
gammopathy of renal significance. Br J Haematol. 2019; 186(5):706-716. 
 
 I contributed towards data collection, contextualisation and prioritisation of findings. I 
supported the first author in writing the manuscript. I estimate my total contribution at 15% 
 
 OP6: Panitsas F, Kothari J, Vallance G, Djebbari F, Ferguson L, Sultanova M, Ramasamy 
K. Treat or palliate: Outcomes of very elderly myeloma patients. Haematologica. 2018; 
103(1):32-34  
I contributed towards review, discussion and feedback about the findings. I contributed 
towards review and editing of the manuscript. I estimate my total contribution at 5-10 % 
 OP7: Willan J, King AJ, Djebbari F, Turner GDH, Royston DJ, Pavord S, Collins GP, 
Peniket A. Assessing the Impact of Lockdown: Fresh Challenges for the Care of 
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Haematology Patients in the COVID-19 Pandemic. Br J Haematol. 2020 May 5. doi: 
10.1111/bjh.16782. [Epub ahead of print] 
I contributed with data collection of chemotherapy patients, those receiving IV rituximab, SC 
bortezomib, and zoledronic acid, in addition to data about autologous transplants and 
allogeneic transplants. I estimate my total contribution to this project to be 25-30%. 
 OP8: Djebbari F, Ramasamy K. Insights into daratumumab. Myeloid and Lymphoid 
Disorders in Practice. 2016; 1(1). 
 
For this review article published in the Myeloid and Lymphoid Disorders in Practice, I 
designed the article and its contents. I have fully written the paper, which was approved by 
the senior author. I estimate my total contribution at 80%. 
 
 OP9: Djebbari F, Schuh A. Venetoclax for 17p deletion chronic lymphocytic leukaemia. 
Myeloid and Lymphoid Disorders in   Practice. 2017; 2(2). 
 
For this review article published in the Myeloid and Lymphoid Disorders in Practice, I 
designed the article and its contents. I have fully written the paper, which was approved by 
the senior author. I estimate my total contribution at 80%. 
 
 OP10: Djebbari F, Spiers L, Mole D, Protheroe A, Tuthill M. Renal cell carcinoma: novel 
medical therapies and management of renal toxicities. British Journal of Renal Medicine. 
2019; 29 (2) 
 
For this review article and management guidance published in the British Journal of Renal 
Medicine, I designed the article and its contents, with support from Dr Tuthill my senior 
author. I have contributed to literature review. I led on writing the manuscript, and 
publication of the paper. 
 
 OP11: Djebbari F, Panitsas F, Sharpley FA, Rampotas A, Larham J, Moore S, Gooding S, 
Kothari J, Ramasamy K. Myeloma care adaptations in the UK during SARS-CoV-2 
pandemic: Challenges and measurable outcomes. Eur J Haematol. 2020 Jun 
26;10.1111/ejh.13479.  doi: 10.1111/ejh.13479.  Online ahead of print. 
 
I conceived this article. I have performed the majority of literature searching and have written 
the paper. I estimate my contribution at 80% 
 
 OP12: Djebbari F, Kaji F, Stanton L, Lawrence MM, Collins GP, Eyre TA. Efficacy and 
infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J 
Haematol. 2020 Jul 15.  doi: 10.1111/ejh.13486.  Online ahead of print. 
I designed the study along with my senior author. I collected data, supported the analysis and 
I have written the paper. I estimate my contribution at least 50% 
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9. APPENDIX 2: TESTIMONIALS FROM CLINICIANS ABOUT 
THE AUTHOR’S PRACTICE-CHANGING RESEARCH:  
Statement from Dr Andy Peniket, Haematology Consultant in Myeloma at Oxford University 
Hospitals NHS Foundation Trust, and Lead Clinician for Bone Marrow Transplant (BMT) at 
Thames Valley Cancer Network (TVCN) 
Statement from Dr Graham P. Collins, Haematology Consultant at Oxford University 
Hospitals NHS Foundation Trust, and Lead Clinician for Lymphoma at Thames Valley 
Cancer Network (TVCN) 
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10. APPENDIX 3: STATEMENTS FROM SENIOR AUTHORS 
(SUPERVISORS) TO CONFIRM AUTHOR CONTRIBUTION:  
Statement from Dr Karthik Ramasamy, Haematology Consultant in Myeloma at Oxford 
University Hospitals NHS Foundation Trust, and Lead Clinician for Myeloma at Thames 
Valley Cancer Network (TVCN). Dr Ramasamy is the senior author and supervisor of all the 
myeloma real-world studies included in this thesis. 
Statement from Dr Verna Lavender, Head of Guy's Cancer Academy, and Honorary Senior 
Clinical Lecturer, School of Cancer & Pharmaceutical Sciences, KCL. Also, President of UK 
Oncology Nursing Society. Dr Lavender is the senior author of the 2 systematic review 
papers: the protocol and the findings. 
Statement from Prof Ana Schuh, Director of Molecular Diagnosis at the University of 
Oxford, Haematology Consultant in CLL at Oxford University Hospitals NHS Foundation 
Trust, and Lead Clinician for CLL at Thames Valley Cancer Network (TVCN) 
Statement from Dr Mark Tuthill, Consultant in Uro-Oncology at Oxford University Hospitals 
NHS Foundation Trust 
 
 
 
